Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
2010-11-2
pubmed:abstractText
Tumors induce new blood vessel growth primarily from host organ microvascular endothelial cells (EC), and microvasculature differs significantly between the lung and liver. Vascular endothelial growth factor (VEGF or VEGF-A) promotion of tumor angiogenesis is thought to be mediated primarily by VEGF receptor-2 (VEGFR-2). In this study, VEGFR-2 antibody (DC101) inhibited growth of RenCa renal cell carcinoma lung metastases by 26%, whereas VEGFR-1 antibody (MF-1) had no effect. However, VEGFR-2 neutralization had no effect on RenCa liver metastases, whereas VEGFR-1 neutralization decreased RenCa liver metastases by 31%. For CT26 colon carcinoma liver metastases, inhibition of both VEGFR-1 and VEGFR-2 was required to induce growth delay. VEGFR-1 or VEGFR-2 inhibition decreased tumor burden not by preventing the establishment of micrometastases but rather by preventing vascularization and growth of micrometastases by 55% and 43%, respectively. VEGF induced greater phosphorylation of VEGFR-2 in lung ECs and of VEGFR-1 in liver ECs. EC proliferation, migration, and capillary tube formation in vitro were suppressed more by VEGFR-2 inhibition for lung EC and more by VEGFR-1 inhibition for liver EC. Collectively, our results indicate that liver metastases are more reliant on VEGFR-1 than lung metastases to mediate angiogenesis due to differential activity of VEGFRs on liver EC versus lung EC. Thus, therapies inhibiting specific VEGFRs should consider the targeted sites of metastatic disease.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1538-7445
pubmed:author
pubmed:copyrightInfo
©2010 AACR.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8357-67
pubmed:dateRevised
2011-11-1
pubmed:meshHeading
pubmed-meshheading:20978198-Animals, pubmed-meshheading:20978198-Antibodies, Neutralizing, pubmed-meshheading:20978198-Blotting, Western, pubmed-meshheading:20978198-Carcinoma, Renal Cell, pubmed-meshheading:20978198-Cell Adhesion, pubmed-meshheading:20978198-Cell Movement, pubmed-meshheading:20978198-Cell Proliferation, pubmed-meshheading:20978198-Cells, Cultured, pubmed-meshheading:20978198-Colonic Neoplasms, pubmed-meshheading:20978198-Endothelium, Vascular, pubmed-meshheading:20978198-Female, pubmed-meshheading:20978198-Fluorescent Antibody Technique, pubmed-meshheading:20978198-Hemangiosarcoma, pubmed-meshheading:20978198-Humans, pubmed-meshheading:20978198-Immunoenzyme Techniques, pubmed-meshheading:20978198-Kidney Neoplasms, pubmed-meshheading:20978198-Liver Neoplasms, pubmed-meshheading:20978198-Lung Neoplasms, pubmed-meshheading:20978198-Mice, pubmed-meshheading:20978198-Mice, Inbred BALB C, pubmed-meshheading:20978198-Mice, Nude, pubmed-meshheading:20978198-Neoplasm Metastasis, pubmed-meshheading:20978198-Neovascularization, Pathologic, pubmed-meshheading:20978198-Organ Specificity, pubmed-meshheading:20978198-RNA, Messenger, pubmed-meshheading:20978198-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20978198-Vascular Endothelial Growth Factor A, pubmed-meshheading:20978198-Vascular Endothelial Growth Factor Receptor-1, pubmed-meshheading:20978198-Vascular Endothelial Growth Factor Receptor-2
pubmed:year
2010
pubmed:articleTitle
Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.
pubmed:affiliation
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural